These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28271502)

  • 21. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
    Abdelsalam RM; Safar MM
    J Neurochem; 2015 Jun; 133(5):700-7. PubMed ID: 25752913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
    Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X
    PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoglycemic effect of D-chiro-inositol in type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway.
    Gao YF; Zhang MN; Wang TX; Wu TC; Ai RD; Zhang ZS
    Mol Cell Endocrinol; 2016 Sep; 433():26-34. PubMed ID: 27212205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug.
    Ali MA; El-Abhar HS; Kamel MA; Attia AS
    PLoS One; 2015; 10(8):e0134648. PubMed ID: 26262991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway.
    Gandhi GR; Jothi G; Antony PJ; Balakrishna K; Paulraj MG; Ignacimuthu S; Stalin A; Al-Dhabi NA
    Eur J Pharmacol; 2014 Dec; 745():201-16. PubMed ID: 25445038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
    Korish AA
    Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
    Akarte AS; Srinivasan BP; Gandhi S
    Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Forst T; Dworak M; Berndt-Zipfel C; Löffler A; Klamp I; Mitry M; Pfützner A
    Diabetes Obes Metab; 2013 Jun; 15(6):576-9. PubMed ID: 23384119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, Tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats.
    Amin MM; Asaad GF; Abdel Salam RM; El-Abhar HS; Arbid MS
    PLoS One; 2014; 9(2):e89169. PubMed ID: 24586567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico and in vivo analysis to identify the antidiabetic activity of beta sitosterol in adipose tissue of high fat diet and sucrose induced type-2 diabetic experimental rats.
    Ponnulakshmi R; Shyamaladevi B; Vijayalakshmi P; Selvaraj J
    Toxicol Mech Methods; 2019 May; 29(4):276-290. PubMed ID: 30461321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The scientific evidence: vildagliptin and the benefits of islet enhancement.
    Mathieu C
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
    Ahrén B; Foley JE; Bosi E
    Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
    Hoste J; Daci E; Mathieu C
    Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects.
    Wang X; Liu R; Zhang W; Zhang X; Liao N; Wang Z; Li W; Qin X; Hai C
    Mol Cell Endocrinol; 2013 Aug; 376(1-2):70-80. PubMed ID: 23791844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidiabetic, antihyperlipidemic, and antioxidant activities of
    Borah M; Das S
    Indian J Pharmacol; 2017; 49(1):71-76. PubMed ID: 28458426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects.
    Li Y; Zhang T; Cui J; Jia N; Wu Y; Xi M; Wen A
    J Pharm Pharmacol; 2015 Jul; 67(7):997-1007. PubMed ID: 25677570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
    Boschmann M; Engeli S; Dobberstein K; Budziarek P; Strauss A; Boehnke J; Sweep FC; Luft FC; He Y; Foley JE; Jordan J
    J Clin Endocrinol Metab; 2009 Mar; 94(3):846-52. PubMed ID: 19088168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
    Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
    Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.